Saturday, July 24, 2021 7:51:41 PM
PAGE M8, CHARTING THE MARKET, BARRONS HAS FEATURED A NICE LITTLE ARTICLE AND A GRAPH ON NRX PHARMACEUTICALS
CAPTION ABOVE THE GRAPH IS.............
A Phase 3 trial indicated that the companys investigational product Zyesami prevents the immunne system overreaction that can be deadly in Covid patients.
THIS IS HUGE GOOD NEWS......IF THE WALL STREET MONEY CROWD GETS ON THIS, LOOK OUT BABY.....
My opinion is reflected in my posts, and it is never advice to buy, sell or trade any securities. Do your own due diligence before purchasing anything in the stock market.
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM